Literature DB >> 24857127

Chemotherapy for lung cancers: here to stay.

Mark G Kris1, Matthew D Hellmann1, Jamie E Chaft1.   

Abstract

Four decades of clinical research document the effectiveness of chemotherapy in patients with lung cancers. Chemotherapeutic agents can improve lung cancer symptoms, lengthen life in most patients with lung cancers, and enhance curability in individuals with locoregional disease when combined with surgery or irradiation. Chemotherapy's effectiveness is enhanced in patients with EGFR-mutant and ALK-positive lung cancers and can "rescue" individuals whose oncogene-driven cancers have become resistant to targeted agents. As immunotherapies become part of the therapeutic armamentarium for lung cancers, chemotherapeutic drugs have the potential to modulate the immune system to enhance the effectiveness of immune check point inhibitors. Even in this era of personalized medicine and targeted therapies, chemotherapeutic agents remain essential components in cancer care.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24857127     DOI: 10.14694/EdBook_AM.2014.34.e375

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  1 in total

Review 1.  Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.

Authors:  Thu Oanh Dang; Adebayo Ogunniyi; Meagan S Barbee; Alexander Drilon
Journal:  Expert Rev Anticancer Ther       Date:  2016       Impact factor: 4.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.